Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2017/0247472 ANTI-AGE ANTIBODIES FOR TREATING INFLAMMATION AND AUTO-IMMUNE DISORDERS
A composition for treating inflammation or auto-immune disorders comprises (i) an antibody that binds to an AGE-modified protein on a cell, and (ii) an...
2017/0247471 HUMAN-DERIVED ANTI-DIPEPTIDE REPEATS (DPRS) ANTIBODY
Provided are novel human-derived dipeptide repeat (DPR) specific antibodies as well as synthetic variants and biotechnological derivatives thereof, preferably...
2017/0247469 MODULATION OF PTPRA TO TREAT ARTHRITIS
Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (PT-PRA) antagonist.
2017/0247468 COMPOSITIONS FOR INHIBITION OF QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAME
A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which...
2017/0247467 BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor...
2017/0247466 TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject a therapeutically...
2017/0247465 COMBINATION THERAPY FOR TREATMENT OF CANCER
The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors...
2017/0247464 Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and...
The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived...
2017/0247463 Modulating Agonistic TNFR Antibodies
The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell...
2017/0247462 TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA
The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis...
2017/0247461 DAC HYP COMPOSITIONS
The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.
2017/0247460 ANTI-IL-7R ANTIBODY COMPOSITIONS
The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a high...
2017/0247459 COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
The present invention relates to the combination therapy of antibodies binding to human CSF-1R, characterized in binding to the (dimerization) domains D4 to D5...
2017/0247458 Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
There is disclosed a chimeric cetuximab-like monoclonal antibody (CMAB009 mAb) having at least 80% NANA glycosylation terminal sialic acid at an ...
2017/0247457 METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid...
2017/0247456 ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or...
2017/0247455 TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective...
2017/0247454 ANTI-PD1 ANTIBODIES AND METHODS OF USE
The present invention relates to anti-PD1 antibodies and methods of using the same.
2017/0247453 SOLUBLE ENGINEERED MONOMERIC FC
Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain...
2017/0247452 Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
CD 19.times.CD3 bi-specific monovalent diabodies, and particularly, CD 19.times.CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to...
2017/0247451 HUMAN PAC1 ANTIBODIES
Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments...
2017/0247450 IMMUNOLOGICAL TREATMENT OF CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND...
The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with...
2017/0247449 THERAPEUTIC METHOD AND MEDICAMENT FOR CANCER PATIENTS BY FOLR1-TARGETING DRUG AND AN ANTAGONIST FOR FOLIC ACID...
The invention provides a method for treating a cancer with a human FOLR1-targeting drug by increasing an expression of folate receptor .alpha. (hereinafter...
2017/0247448 HUMANIZED ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF
The present application relates to humanized antibodies that specifically bind to hepcidin and methods of using the humanized antibodies. Another aspect...
2017/0247447 ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody...
2017/0247446 TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
The present invention provides method of treating a K-Ras-expressing cancer in a subject comprising administering to the subject a therapeutic amount of an...
2017/0247445 MAMMALIAN CELL CULTURE PERFORMANCE THROUGH SURFACTANT SUPPLEMENTATION OF FEED MEDIA
The present invention provides methods for increasing cell culture performance through the use of chemically defined feed media (CDFM). In particular, the...
2017/0247444 ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES
The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain...
2017/0247443 Safety and Efficacy with a CHO Cell Glycosylated Chimeric Antibody to TNF
There is disclosed a chimeric infliximab-like monoclonal antibody having at least 80% NANA glycosylation terminal sialic acid and a glycosylation pattern of...
2017/0247442 USE OF ANTI-EOTAXIN ANTIBODIES FOR TREATING INFLAMMATORY BOWEL DISEASE
The present invention provides use of one or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains in non-native antibody...
2017/0247441 ANTI-ANG2 ANTIBODIES AND METHODS OF USE
Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, (b) a...
2017/0247440 ANTI-PDGF-B ANTIBODIES AND METHODS OF USE
Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
2017/0247439 METHODS FOR TREATING OSTEOGENESIS IMPERFECTA
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a...
2017/0247438 SHARK ANTIBODIES FOR CANCER THERAPY
Sharks have been thriving for over 500 million years. Sharks evolved some of the first adaptive antibodies and developed immunoglobulin M (IgM) as their...
2017/0247437 RSPO1 BINDING AGENTS AND USES THEREOF
The present invention relates to RSPO-binding agents, particularly antibodies that specifically bind human RSPO1. Also described are methods of treating cancer...
2017/0247436 NON-HUMAN ANIMALS HAVING A MUTANT KYNURENINASE GENE
Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a mutant L-kynurenine...
2017/0247435 BISPECIFIC HIV-1 NEUTRALIZING ANTIBODIES
In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.
2017/0247434 NOROVIRUS ANTIBODIES
The present invention relates to a binding polypeptide specifically binding to the amino acid sequence W-V-N-X.sup.1-F-Y-X.sup.2 (SEQ ID NO: 1), wherein...
2017/0247433 IMPROVED PROCESS FOR THE PREPARATION OF IMMUNOGLOBULIN G (IgG)
The present invention is directed to processes for extracting IgG from an unused waste precipitate produced during normal plasma fractionation processes via a...
2017/0247432 DISPLAY OF BINDING AGENTS
The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a...
2017/0247431 Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid...
2017/0247430 NOVEL BIOFABRICATION TECHNIQUES FOR THE IMPLEMENTATION OF INTRINSIC TISSUE GEOMETRIES TO AN IN VITRO COLLAGEN...
Methods for reaction electrospinning are provided to form collagen fibers. The method can include: acidifying a collagen in an acidic solvent to form an acidic...
2017/0247429 BLOOD-BRAIN BARRIER DISRUPTING AGENTS AND USES THEREOF
The present invention relates to blood-brain barrier disrupting agents containing a modified serum albumin comprising serum albumin. The present invention...
2017/0247428 Chimeric Antigen Receptors
A chimeric antigen receptor (CAR) comprising an extracellular spacer which comprises at least part of the extracellular domain of human low affinity nerve...
2017/0247427 TRAIL CELL-PENETRATING PEPTIDE-LIKE MUTANT MUR5, PREPARATION METHOD AND APPLICATION THEREOF
A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID...
2017/0247426 MODIFIED GLYCOPROTEINS
Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
2017/0247425 RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY
The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12...
2017/0247424 TRAIL CELL-PENETRATING PEPTIDE-LIKE MUTANT MUR6, PREPARATION METHOD AND APPLICATION THEREOF
A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR6 and a preparation method and the application thereof. The amino acid sequence of the mutant is SEQ ID...
2017/0247423 STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION
Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert...
2017/0247422 EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) PEPTIDES AND BINDING ANTIBODIES
Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.